Leukemia, Myeloid: all 2,432 studies
Page 11 of 25. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.
- Efficacy of Antibiotic Short Course for Bloodstream Infections in Acute Myeloid Leukemia Patients With Febrile NeutropeniaCompletedNCT04910698
- Feasibility Pilot Exploring Variability in Biomarkers and PROs in AMLCompletedNCT04908852
- Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 MutationsStatus unknownNCT04906031Phase 2
- HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation CyclophosphamideActive, not recruitingNCT04904588Phase 2
- Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML.Status unknownNCT04904237Phase 2
- A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid LeukemiaWithdrawnNCT04896112Phase 1
- Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDSWithdrawnNCT04893915Phase 2
- A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)CompletedNCT04887857Phase 1
- Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)Status unknownNCT04884984Phase 1/2
- Value of Using Pioglitazone in Chronic Myeloid Leukemia TreatmentCompletedNCT04883125Phase 2
- Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid LeukemiaStatus unknownNCT04867928Phase 2
- Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic SyndromesActive, not recruitingNCT04861207Phase 2
- Study of Periodontitis and Blood Stream Infection in AML Patients Receiving ChemotherapyTerminatedNCT04858594
- Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AMLStatus unknownNCT04842370Phase 1
- Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT04835519Phase 1/2
- A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)CompletedNCT04827069Phase 1
- A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive ChemotherapyStatus unknownNCT04824924Phase 2
- TIGIT in Patients With Chronic Myeloid LeukemiaStatus unknownNCT04818619
- Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid LeukemiaCompletedNCT04813263
- A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous LeukemiaStatus unknownNCT04806659Phase 1
- Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT04789655Phase 1
- Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AMLCompletedNCT04788420
- Effect of Digital Health Coaching Program on Self-efficacy and Patient Reported Outcomes of Patients With Newly Diagnosed Acute Myeloid Leukemia or Chronic Lymphocytic LeukemiaCompletedNCT04774744Not applicable
- Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and VenetoclaxActive, not recruitingNCT04763928Phase 2
- A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)TerminatedNCT04755244Phase 1
- Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk FeaturesStatus unknownNCT04752527Phase 2
- A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive TherapyTerminatedNCT04748848Phase 1
- Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients.Status unknownNCT04747002Phase 2
- A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With AML and MDSStatus unknownNCT04743115Phase 1
- PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AMLStatus unknownNCT04722952Phase 3
- Safety and Early Efficacy Study of TBX-2400 in Patients With AML or MyelofibrosisStatus unknownNCT04709458Phase 1
- Prognostic Value of CD318 in AML at Assiut University Hospital.Status unknownNCT04708444
- A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid LeukemiaCompletedNCT04694820Not applicable
- TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid LeukemiaStatus unknownNCT04692948Not applicable
- Risk-adapted Therapy for Primary Acute Myeloid LeukemiaCompletedNCT04687098Phase 2
- Flotetuzumab Expanded Access ProgramNo longer availableNCT04678466
- TL-895 and KRT-232 Study in Acute Myeloid LeukemiaActive, not recruitingNCT04669067Phase 1/2
- Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell TransplantationWithdrawnNCT04655391Phase 1
- Innate T Cells and TKI DiscontinuationActive, not recruitingNCT04645706
- A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid NeoplasmsTerminatedNCT04637009Phase 1
- A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid LeukemiaStatus unknownNCT04632316Phase 1/2
- IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT04628338Early Phase 1
- Aerobic Versus Resistive Training on Functional Capacity in Acute Myeloid LeukemiaCompletedNCT04617145Not applicable
- FT538 in Subjects With Advanced Hematologic MalignanciesTerminatedNCT04614636Phase 1
- A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase InhibitorsCompletedNCT04605211Not applicable
- A Multicentre, Retrospective Study to Evaluate the Outcome of HSCT Mismatch Unrelated DonorsCompletedNCT04598789
- Effects of a Digital Patient Platform (CMyLife) for Patients With Chronic Myeloid Leukemia (CML) on Information Provision, Patient Empowerment, Medication Compliance, Guideline Adherence and Quality of LifeCompletedNCT04595955Not applicable
- A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.CompletedNCT04580121Phase 1
- A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)Status unknownNCT04578847Phase 2
- Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive ChemotherapyStatus unknownNCT04541277Phase 2
- Diagnosis and Treatment of Periodontal Disease in Patients With AMLWithdrawnNCT04530695Not applicable
- Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory LeukemiaTerminatedNCT04526795Phase 1
- IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCTCompletedNCT04522895Phase 2
- Nilotinib, for Patients With CML-CP or CML-APNo longer availableNCT04518644
- TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid LeukemiaCompletedNCT04518345Early Phase 1
- A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)CompletedNCT04509622Phase 3
- Phase 1 First in Human Study of ZN-d5 as a Single AgentCompletedNCT04500587Phase 1
- Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AMLWithdrawnNCT04493099Phase 1/2
- Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AMLStatus unknownNCT04490707Phase 3
- Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid LeukemiaSuspendedNCT04485052Phase 1/2
- A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDSTerminatedNCT04477291Phase 1
- Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCTActive, not recruitingNCT04476199Phase 2
- HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell TransplantationWithdrawnNCT04464889Phase 1
- Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive ChemotherapyStatus unknownNCT04454580
- ObServatory Children Acute RElated Therapy LeukemiaStatus unknownNCT04450784
- Molecular Diagnostic Platform for AMLStatus unknownNCT04446741
- Phase III rhu_GM-CSF + 3 Induction Regimens in Adults With Acute Non-Lymphocytic LeukemiaCompletedNCT04446052Phase 3
- Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.TerminatedNCT04425655Phase 2
- Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAMLCompletedNCT04424147Phase 2
- Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid LeukemiaActive, not recruitingNCT04415008Phase 2
- Endogenous Retroviruses in Acute Myeloid LeukemiaWithdrawnNCT04406207
- Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT04402541Phase 1
- Outcomes of Acute Myeloid Leukemia PatientsStatus unknownNCT04392310
- Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)Status unknownNCT04373395Not applicable
- Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid LeukemiaStatus unknownNCT04369287
- Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant CyclophosphamideWithdrawnNCT04361058Phase 1
- Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AMLWithdrawnNCT04354025Phase 2
- Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid LeukemiaStatus unknownNCT04353479Phase 2
- CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapesd or Refractory Acute Myeloid LeukemiaStatus unknownNCT04351022Phase 1/2
- Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid LeukemiaTerminatedNCT04342962Phase 2
- A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid LeukemiaTerminatedNCT04336982Phase 1
- Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm TreatmentCompletedNCT04321161Early Phase 1
- Natural Killer Cell (CYNK-001) Infusions in Adults with AMLTerminatedNCT04310592Phase 1
- Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid LeukemiaWithdrawnNCT04296214
- Immunophenotyping and Xist Gene in AMLStatus unknownNCT04288739
- A Study of TAS1440 With ATRA in Subjects With r/r AMLTerminatedNCT04282668Phase 1
- CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic MalignanciesWithdrawnNCT04282174Phase 2
- A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/NeoplasmsStatus unknownNCT04272957Phase 1
- A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated CancersTerminatedNCT04272203Phase 1
- Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity ScreeningCompletedNCT04267081Phase 2
- CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT04265963Phase 1/2
- Analysis of T Cell Metabolism in Acute Myeloid Leukemia PatientsCompletedNCT04259372
- Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AMLStatus unknownNCT04254640Phase 2
- A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian FederationCompletedNCT04253314
- Study of Azacitidine Combined With Homoharringtonie Based Regimens in AMLStatus unknownNCT04248595Phase 2
- A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive TreatmentCompletedNCT04241549Phase 1
- Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital StayStatus unknownNCT04240600Not applicable
- Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute LeukemiaActive, not recruitingNCT04232241Phase 2
- Acute Myeloid Leukemia Real World Treatment PatternsWithdrawnNCT04230564
- NK Cell Infusion for Patients With Acute Myeloid LeukemiaStatus unknownNCT04221971Phase 1